Merck & Co.: pipeline and clinical trials
Merck & Co. (MSD outside the U.S. and Canada) developed enlicitide, approved by the FDA in July 2026 as Lipfendra, the first oral PCSK9 inhibitor. Merck sponsors more than 220 active clinical trials, with oncology the most common focus.
Key points
- Merck sponsors 228 active trials on ClinicalTrials.gov, including 99 in Phase 3. Cancers, especially lung cancer, are among the most frequently listed conditions.
- The FDA approved Lipfendra (enlicitide) on July 15, 2026, as the first oral PCSK9 inhibitor for lowering LDL cholesterol.
- Lipfendra received Priority Review and was reviewed under the FDA Commissioner's National Priority Voucher pilot.
- The enlicitide cardiovascular outcomes trial, with an estimated 14,550 participants, is Merck's largest active Phase 3 trial.
- Merck reports that its TROP2 antibody–drug conjugate sacituzumab tirumotecan is under FDA priority review for previously treated endometrial cancer, with a June 15, 2027 target date.
- Merck & Co. is a separate company from Merck KGaA of Darmstadt, Germany, which has agreed to acquire Silence Therapeutics.
Tracked drug profiles
Drugs from this company that Spectral Genomics profiles in depth, with registry data and sourced analysis.
Enlicitide (Lipfendra)
Oral PCSK9 inhibitor (once-daily tablet) · Cardiovascular
FDA-approved July 2026 as the first oral PCSK9 inhibitor; cardiovascular outcomes trial ongoing
Approved outside the U.S.Sacituzumab tirumotecan
Antibody–drug conjugate (ADC) · Oncology
Approved in China since 2024; under FDA priority review for previously treated endometrial cancer, decision date June 15, 2027 (company-reported)
Active clinical trials
ClinicalTrials.gov lists 228 active trials with Merck & Co. as lead sponsor (recruiting, not yet recruiting, active, or enrolling by invitation), retrieved Nov 19, 2026. Counts include only trials whose lead sponsor is registered as "Merck Sharp & Dohme LLC".
By phase
| Phase 1 | 30 |
| Phase 1/2 | 34 |
| Phase 2 | 52 |
| Phase 2/3 | 8 |
| Phase 3 | 99 |
| Phase 4 | 3 |
| Not applicable | 2 |
Most common conditions
- Malignant Neoplasm (11)
- Non-small Cell Lung Cancer (10)
- Advanced Solid Tumors (7)
- Papillomavirus Infections (6)
- Carcinoma, Non-Small-Cell Lung (6)
- Carcinoma, Renal Cell (6)
- Bladder Cancer (6)
- Breast Neoplasms (6)
Conditions as registered by the sponsor; one trial can list several.
Largest active Phase 3 trials
| Trial | Enrollment | Primary completion |
|---|---|---|
| NCT06008756 Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes | 14,550 | Nov 29, 2029 |
| NCT07013487 A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1) | 12,000 | Sep 6, 2031 |
| NCT05285826 Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) | 8,100 | May 25, 2029 |
| NCT04199689 Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 6,033 | Jan 15, 2027 |
| NCT03998254 Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023) | 6,000 | Mar 31, 2028 |
| NCT07071623 A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) | 4,580 | Oct 18, 2027 |
| NCT07044297 A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | 4,390 | Jul 22, 2027 |
| NCT03486873 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | 3,500 | Aug 4, 2043 |
| MOVe-NOW · NCT06667700 A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) | 3,082 | Jan 26, 2031 |
| NCT06492291 Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension | 3,000 | Oct 13, 2028 |
Enlicitide and cardiovascular medicine
Enlicitide brings PCSK9 inhibition, until now available only by injection, to a once-daily pill. Its approval rests on LDL lowering. The outcomes trial testing whether it reduces heart attacks and strokes is the company's largest active Phase 3 study, with an estimated primary completion in November 2029.
A broader pipeline
Merck's registry footprint is dominated by oncology and vaccines. Among its largest active Phase 3 trials are a dengue vaccine study in children (V181) and studies of its 9-valent HPV vaccine. In oncology, Spectral Genomics profiles sacituzumab tirumotecan, a TROP2-directed antibody–drug conjugate licensed from Kelun-Biotech that improved overall survival in previously treated endometrial cancer.
What to watch
- CORALreef Outcomes, estimated primary completion November 2029 (registry).
- Regulatory decisions for Lipfendra outside the U.S.
- The FDA decision on sacituzumab tirumotecan for endometrial cancer, due by June 15, 2027 (company-reported).
Recent milestones
- Oct 9, 2023Enlicitide cardiovascular outcomes trial (CORALreef Outcomes) begins. Registry
- Feb 5, 2026CORALreef Lipids results published: LDL −57.1% versus +3.0% with placebo. Peer-reviewed
- Jul 15, 2026FDA approves Lipfendra (enlicitide), the first oral PCSK9 inhibitor. Regulator
Sources
- SEC EDGAR: Merck & Co., Inc. filings (CIK 310158).Regulator
- U.S. Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (July 17, 2026).Regulator
- Navar AM, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. New England Journal of Medicine. 2026;394(6):529–539.Peer-reviewed
- ClinicalTrials.gov: active trials with this lead sponsorRegistry
This page is for education and research. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported information is labeled. See our disclaimer.